Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex ( (ENLV) ) has shared an update.
On March 4, 2025, Enlivex Therapeutics announced an investor webinar to discuss positive interim data from the Phase I stage of its Allocetra™ trial for knee osteoarthritis. The results showed a significant reduction in pain and improvement in joint function, with no serious adverse events reported, highlighting Allocetra™’s potential as a breakthrough treatment in a field with unmet medical needs.
More about Enlivex
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in macrophage reprogramming immunotherapy. The company is developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state, which is crucial for immune system rebalancing and addressing life-threatening and debilitating conditions.
YTD Price Performance: -3.23%
Average Trading Volume: 113,965
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $26.39M
See more data about ENLV stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money